Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-760 plus R-GemOx vs placebo plus R-GemOx in relapsed/refractory DLBCL
CTR20254776Phase 3Active
- Sponsor
- HUTCHMED
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HMPL-760 in diffuse large B-cell lymphoma (DLBCL), sponsored by HUTCHMED. Started Mar 2026; status: active.
02
Drugs
HMPL-760
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20254776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254776.